» Articles » PMID: 17925086

Improved Survival Rate for Women with Interval Breast Cancer - Results from the Breast Cancer Screening Programme in Malmö, Sweden 1976-1999

Overview
Journal J Med Screen
Specialty Public Health
Date 2007 Oct 11
PMID 17925086
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Breast cancers detected between screening examinations can influence the sensitivity of a screening programme. Studies of the prognosis of these so-called interval breast cancers show diverging results. We investigated the course of interval breast cancer over time in the Malmö Mammographic Screening Trial (MMST) 1976-86 and the Malmö Mammographic Service Screening Programme (MMSSP) 1990-99.

Material And Methods: Stage distribution and survival of interval cancers in MMSSP were compared with screen-detected and non-attender cancer cases in MMSSP, with interval cancers in MMST and with breast cancer cases in a non-screened population five years before the start of MMSSP (pre-screening cancer cases).

Results: In MMSSP 1990-99, the interval cancers did not differ in stage distribution or survival compared with cancer cases in non-attenders, while screen-detected cancer cases had more favourable stage distribution and rate of survival than had the interval cancer cases. The MMST interval cancer cases, 1976-1986, had more favourable stage distribution but higher overall case fatality rate, relative risks (RR) 1.78 (1.00-3.20), and breast cancer case fatality rate, RR 2.05 (1.05-4.00), compared with the more recent MMSSP interval cancer cases. No significant difference in five-year survival was seen in the MMSSP interval cancer cases compared with pre-screening cancer cases not exposed to screening.

Conclusion: In this urban population invited to mammographic screening, the survival rate for women with interval cancer has improved over a period of 20 years. Further studies are needed to assess what factors might explain changes in the course of interval breast cancer.

Citing Articles

Radiological features of screening-detected and interval breast cancers and subsequent survival in Eastern Finnish women.

Nykanen A, Sudah M, Masarwah A, Vanninen R, Okuma H Sci Rep. 2024; 14(1):10001.

PMID: 38693256 PMC: 11063164. DOI: 10.1038/s41598-024-60740-0.


Breast Cancer Screening Program in Lithuania: Interval Cancers and Program Sensitivity After 7 Years of Mammography Screening.

Steponaviciene L, Vincerzevskiene I, Briediene R, Urbonas V, Vanseviciute-Petkeviciene R, Smailyte G Cancer Control. 2019; 26(1):1073274819874122.

PMID: 31502471 PMC: 6755864. DOI: 10.1177/1073274819874122.


Differences between screen-detected and interval breast cancers among BRCA mutation carriers.

Pilewskie M, Zabor E, Gilbert E, Stempel M, Petruolo O, Mangino D Breast Cancer Res Treat. 2019; 175(1):141-148.

PMID: 30673971 PMC: 6494691. DOI: 10.1007/s10549-018-05123-6.


Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers.

Defossez G, Quillet A, Ingrand P BMC Cancer. 2018; 18(1):393.

PMID: 29625602 PMC: 5889614. DOI: 10.1186/s12885-018-4319-4.


The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening.

Houssami N, Hunter K NPJ Breast Cancer. 2017; 3:12.

PMID: 28649652 PMC: 5460204. DOI: 10.1038/s41523-017-0014-x.